THURSDAY, July 11, 2019 (HealthDay News) — Two experimental Ebola treatments being used in the current outbreak in eastern Democratic Republic of the Congo proved effective in laboratory tests with human cells, the U.S. Centers for Disease Control and Prevention says.
Latest Infectious Disease News
The tests showed that the treatments — the antiviral remdesivir and antibodies in the ZMapp treatment — blocked growth of the Ebola virus strain causing the outbreak.
The findings suggest that the two treatments hold promise for enabling patients to recover from the deadly illness, according to the CDC.
The study was published July 9, in the journal Lancet Infectious Diseases.
“All of the treatments being tested in the current DRC outbreak were developed to fight Ebola viruses from previous outbreaks,” lead author Laura McMullan, a CDC microbiologist, said in an agency news release.
“RNA viruses are always mutating — and because Ebola is an RNA virus it’s vitally important to make sure existing treatments work against the virus that’s making people sick now,” she said.
Copyright © 2019 HealthDay. All rights reserved.